148763-41-1

Basic information

• Product Name: Methyl N-Boc-piperidine-3-carboxylate
• Synonyms: TERT-BUTYL METHYL PIPERIDINE-1,3-DICARBOXYLATE;METHYL N-BOC-NIPECOTATE;1-TERT-BUTYL 3-METHYL PIPERIDINE-1,3-DICARBOXYLATE;N-Boc-nipecotic acid methyl ester;N-Boc- Piperidine-3-carboxylate;Methyl N-Boc-piperidine-3-carboxylate;REF DUPL: Methyl N-Boc-piperidine-3-carboxylate;N-Boc-piperidine-3-carboxylate Methyl
• CAS NO: 148763-41-1
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 148763-41-1.mol

Chemical Properties

• Melting Point: 47.0 to 51.0 °C
• Boiling Point: 307.4 °C at 760 mmHg
• Flash Point: 139.7 °C
• Appearance: Reddish brown viscous liquid
• Density: 1.094 g/cm³
• Vapor Pressure: 0.000726mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.48±0.40(Predicted)
• CAS DataBase Reference: Methyl N-Boc-piperidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl N-Boc-piperidine-3-carboxylate(148763-41-1)
• EPA Substance Registry System: Methyl N-Boc-piperidine-3-carboxylate(148763-41-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 148763-41-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(15)13-7-5-6-9(8-13)10(14)16-4/h9H,5-8H2,1-4H3

Upstream product

• 67-56-1 methanol 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 89895-55-6 methyl piperidine-3-carboxylate hydrochloride 
• 59-67-6 nicotinic acid 
• 149-73-5 trimethyl orthoformate 
• 50585-89-2 3-methoxycarbonylpiperidine 
• 498-95-3 nipecotic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 6034-80-6 piperidine-3-carboxylic acid hydrochloride 

Downstream Products

• 50585-89-2 3-methoxycarbonylpiperidine 
• 1349644-17-2 1-(1,1-dimethylethyl)-3-methyl-3-(2-propen-1-yl)-1,3-piperidinedicarboxylate 
• 441774-03-4 3-methoxycarbonylmethyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylmethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 888952-55-4 1-(tert-butyl) 3-methyl 3-methylpiperidine-1,3-dicarboxylate 
• 934342-31-1 3-fluoropiperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 934342-39-9 1-(tert-butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid 
• 688809-97-4 3-[(methyloxy)methyl]piperidine hydrochloride 
• 868065-26-3 t-butyl 3-(methoxymethyl)piperidine-1-carboxylate 
• 374795-33-2 (RS)-1,1-dimethylethyl 2-oxa-1-oxo-7-azaspiro[4,5]decan-7-carboxylate 

Relevant articles and documents

Di-oxanipecotic acids as more stable turn motifs than di-nipecotic acids

The folded structures of peptidomimetics containing dimers of oxanipecotic acid (Oxa) in loop segments were characterized and compared with those of the corresponding nipecotic acid (Nip)-based ones. According to structural studies using FT-IR and NMR spectroscopies, di-oxanipecotic acid adopted more stable turn conformations than di-nipecotic acid, and for tetramers, L,(S)-Oxa,(S)-Oxa,L and L,(S)-Oxa,(R)-Oxa,L formed hairpin-like structures but only L,(R)-Nip,(S)-Nip,L promoted the stable folded conformations.

Design and Synthesis of 56 Shape-Diverse 3D Fragments

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

Preparation method of 5-bromopyrimidine compound

The present invention discloses a preparation method of a 5-bromopyrimidine compound (1-(5-bromopyrimidine-2-yl)piperidine-3-yl)methylamine, wherein N-Boc-3-piperidinecarboxylic acid is used as a starting raw material, and esterification, reduction, condensation, substitution, tertbutyloxycarbonyl protection removing, condensation and reduction are performed to obtain the target product. According to the present invention, the compound is the important pharmaceutical intermediate.

SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS

The invention relates to novel spirocyclic derivatives with affinity for Cav2.2 calcium channels and which are capable of interfering with Cav2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy for the treatment of pain.

Chemoenzymatic approach to enantiopure piperidine-based β-amino esters in organic solvents

This research concentrates on the enantioselectivities of lipase-catalysed reactions with methyl esters of 2-piperidylacetic acid and 3-piperidinecarboxylic acid derivatives. N-Acetylated 2-piperidylacetic acid methyl ester displayed good enantioselectivi

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Therapeutic pyrazolo[3,4-B]pyridines and indazoles

The present invention provides for compounds of Formula I: wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

Synthesis and structure-activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors

Replacement of the amide functionality in IM491 (N-hydroxy-(5S,6S)-1- methyl-6-{[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl} -5-piperidinecarboxamide) with a sulfonyl group led to a new series of α,β-cyclic and β,β-cyclic γ-sulfonyl hydroxamic acids, which were potent TNF-α converting enzyme (TACE) inhibitors. Among them, inhibitor 4b (N-hydroxy-(4S,5S)-1-methyl-5-{[4-(2-methyl-4- quinolinylmethoxy)phenyl]sulfonylmethyl}-4-pyrrolidinecarboxamide) exhibited IC50 values of 1 nM and 180 nM in porcine TACE (pTACE) and cell assays, respectively, with excellent selectivity over MMP-1, -2, -9 and -13 and was orally bioavailable with an F value of 46% in mice.